A pathologist's perspective on emerging genomic tests for breast cancer.
Emerging molecular tests for breast cancer indicate how future progress in diagnostic pathology might guide patient care. However, the challenge will be to bring the best results from this exciting research into clinical use as accurate and reliable standardized tests that integrate into the diagnostic work-up.
Symmans
W Fraser
WF
Department of Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA. fsymmans@mdanderson.org
D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D005260:Female; D020869:Gene Expression Profiling; D023281:Genomics / Q000639:trends*; D006801:Humans; D008403:Mass Screening; D011379:Prognosis; D013048:Specimen Handling
D014408:Biomarkers, Tumor